TRAF3IP2: E3 ubiquitin ligase TRAF3IP2
E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on TRAF3IP2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Iguratimod | Phase 3 | Eisai | Small molecule | InhibitorE3 ubiquitin ligase TRAF3IP2 inhibitor | 6 |
| Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis | Iguratimod | Not applicable | Not yet recruiting | Wangjing Hospital, China Academy of Chinese Medical Sciences | Aug 11, 2025 |
| Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP | Iguratimod | Phase 2 | Not yet recruiting | Peking University People's Hospital | Jul 10, 2025 |
| A Study of Iguratimod in Combination With Tofacitinib in RA Patients | Iguratimod | Phase 4 | Not yet recruiting | Jie Chang | Apr 25, 2025 |
| Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD | Iguratimod | Phase 1 / Phase 2 | Recruiting | Xuzhou Medical University | Feb 6, 2024 |
| Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement | Iguratimod | Not applicable | Recruiting | Peking Union Medical College Hospital | Mar 29, 2023 |
| The Clinical Efficacy of Immunomodulators in RA Patients | Iguratimod | Phase 4 | Recruiting | Qilu Hospital of Shandong University | Nov 23, 2022 |
- Chronic mucocutaneous candidiasis0.72
- Psoriasis0.68
- Rheumatoid arthritis0.58
- Psoriatic arthritis0.55
- Psoriasis vulgaris0.54
- Skin disorder0.45
- Type 2 diabetes mellitus0.41
- Neurodegenerative disease0.41
- Inflammatory bowel disease0.40
- Candidiasis, familial, 80.38
- Autoimmune disease0.36
- Discoid lupus erythematosus0.34
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4523586, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O43734, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets